Shuttle Pharmaceuticals
SHPH
4 hedge funds and large institutions have $61.5K invested in Shuttle Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
61% less capital invested
Capital invested by funds: $158K → $61.5K (-$96.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
+$25.6K |
| 2 |
Renaissance Technologies
New York
|
+$14.3K |
| 3 |
VF
Virtu Financial
New York
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$1.02K |
SHPH Hedge Fund Activity: Q4 2023 in Review
4 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q4 2023, worth a combined $61.5K — down 61% from $158K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SHPH positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was StoneX Group, opening a new position worth an estimated $25.6K. The largest seller was Federation des caisses Desjardins du Quebec, exiting entirely with an estimated $1.02K sold.
- 4 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q4 2023, up from 3 in Q3 2023.
- Funds reported $61.5K of Shuttle Pharmaceuticals stock for Q4 2023, down 61% quarter-over-quarter.
- 3 funds opened new Shuttle Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +2 holders.
- The largest Shuttle Pharmaceuticals buyer in Q4 2023 was StoneX Group, an estimated $25.6K added.
- The largest Shuttle Pharmaceuticals seller in Q4 2023 was Federation des caisses Desjardins du Quebec, an estimated $1.02K sold.
Based on aggregated 13F filings for Q4 2023.